Do-Youn Oh
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Purpose: Mutant IDH1 (mIDH1) defines a therapeutically targetable subtype of intrahepatic cholangiocarcinoma (ICC), with the mIDH1 inhibitor ivosidenib approved for advanced disease. A subset of patients experiences prolonged disease stabilization; however, the molecular basis for eventual progression remains poorly defined. Experimental Design: We performed molecular profiling of matched baseline and postprogression circulating tumor DNA (ctDNA) samples from patients with mIDH1 ICC enrolled in the ClarIDHy phase III trial. Functional studies were conducted to characterize candidate resistance mechanisms. Results: Longitudinal ctDNA analysis of 18 patients treated with ivosidenib for >6 months revealed emergent genomic alterations in multiple cases. Acquired mutations in mitogen-activated protein kinase (MAPK) pathway genes (KRAS, NRAS, MAP2K1, NF1) were identified in five cases, with instances of concurrent alterations and/or high variant allele fractions (VAF). Additional candidate resistance events included a secondary IDH1 mutation and a hotspot IDH2 mutation, detected at low VAF in the same patient. Functional studies showed that these IDH mutations conferred sustained 2-hydroxyglutarate production and ivosidenib resistance, whereas MAPK activation blunted gene expression induced by ivosidenib plus IFNγ, a key therapeutic output of mIDH1 inhibition. In parallel, baseline ctDNA profiling of 81 patients revealed that ARID1A mutations and elevated mIDH1 VAF were associated with reduced clinical benefit. Conclusions: MAPK pathway alterations represent a recurrent mechanism of resistance to mIDH1 inhibition in ICC, whereas emergent IDH1/IDH2 mutations appear infrequent. Functional data suggest that MAPK-mediated resistance may involve impaired IFN signaling. These results support MAPK-directed combination strategies and highlight the utility of ctDNA profiling to identify predictive and resistance biomarkers in mIDH1-driven ICC.
Year:
2026
Purpose: Isocitrate dehydrogenase (IDH) 1/2–isoform inhibitors have clinical efficacy in IDH1/ IDH2- mutated neoplasms. However, primary resistance and secondary resistance limit their therapeutic potential. LY3410738, an oral, brain-penetrant, dual IDH1/IDH2-mutated isoform-selective inhibitor, was designed to overcome resistance. Patients and Methods: This global, multicenter, open-label, phase I study of patients with IDH- mutant solid tumors evaluated LY3410738 as monotherapy (dose escalation) for advanced solid tumors in combination with cisplatin–gemcitabine (CISGEM) for newly diagnosed cholangiocarcinoma or with durvalumab for relapsed/refractory cholangiocarcinoma (dose expansion; NCT04521686). Primary objectives were the maximum tolerated dose, recommended phase II dose, and preliminary antitumor activity. Safety, pharmacokinetics, inhibition of D-2-hydroxyglutarate, and ctDNA were assessed. Results: Overall, 119 patients received LY3410738 alone ( N = 94) or in combination with CISGEM ( N = 19) or durvalumab ( N = 6). No dose-limiting toxicities were observed; the maximum tolerated dose was not determined. Common adverse events included nausea, vomiting, and decreased appetite. Overall response rates of 5.2% and 11.1% and disease control rates of 56.9% and 63.0% were observed for patients with relapsed/refractory IDH1 - or IDH2 -mutant cholangiocarcinoma or IDH1 -mutant glioma, respectively. D-2-hydroxyglutarate normalization was rapid and durable. In dose-expansion cohorts, combination treatments were tolerable, with one dose-limiting toxicity in the durvalumab cohort. LY3410738 plus CISGEM demonstrated a response rate of 42.1%, a median duration of response of 8.1 months, and a median progression-free survival of 10.2 months for patients with newly diagnosed IDH -mutant cholangiocarcinoma. Conclusions: LY3410738 demonstrated largely cytostatic antitumor activity in IDH1- or IDH2- mutated cholangiocarcinoma and IDH1- mutated gliomas. LY3410738 plus CISGEM exhibited favorable antitumor activity in patients with treatment-naïve IDH- mutated cholangiocarcinoma, warranting further exploration as a treatment strategy.
Year:
2025
Background Trastuzumab resistance in HER2-positive cancers remains a significant clinical challenge with limited therapeutic options. Although the tumor-promoting role of the Yes-associated protein (YAP) pathway is well established, its role in trastuzumab resistance remains unclear. Methods We established four trastuzumab-resistant (HR) cell lines (NCI-N87HR, SNU216HR, SNU2670HR, and SNU2773HR) from HER2-positive gastric cancer and biliary tract cancer cell lines. YAP pathway activation was assessed using Phospho-RTK arrays, bulk RNA-Seq, and immunofluorescence. Antitumor effects of YAP targeting were evaluated with MTT assays, cell-cycle analysis, migration assays, RT-qPCR, ELISA, and xenograft models of SNU-2773 and SNU-2773HR cells. Immune modulation by YAP was studied through co-culture experiments with human PBMCs and cancer cells, followed by flow cytometry analysis of immune markers. Results Upregulation and activation of the YAP/TAZ pathway were observed in HR cells, indicated by elevated ROR2 levels and nuclear translocation of YAP. This activation, driven by YAP/TEAD-dependent Wnt5a expression, suggests a positive-feedback mechanism that amplifies YAP activity. Elevated YAP and TEAD levels were observed in patient tumor tissues during disease progression following HER2-targeted therapies. Targeting YAP disrupted its oncogenic effects and restored sensitivity to trastuzumab, increased activation of CD4 + and CD8 + T cells in PBMCs, likely via PD-L1 downregulation and enhanced immunogenic cell death. Verteporfin, a YAP-TEAD inhibitor, effectively reduced tumor growth and increased apoptosis in mouse models bearing HR tumors. Conclusions Targeting the ROR2-YAP/TEAD axis presents a promising therapeutic approach to overcome trastuzumab resistance in HER2-positive cancers, offering a potential strategy for enhancing treatment efficacy and improving clinical outcomes.
Year:
2025
Purpose: This multicenter phase II basket trial investigated the efficacy, safety, and pharmacokinetics of Debio 1347, an investigational, oral, highly selective, ATP-competitive, small molecule inhibitor of FGFR1–3, in patients with solid tumors harboring a functional FGFR1–3 fusion. Patients and Methods: Eligible adults had a previously treated locally advanced (unresectable) or metastatic biliary tract (cohort 1), urothelial (cohort 2), or another histologic cancer type (cohort 3). Debio 1347 was administered at 80 mg once daily, continuously, in 28-day cycles. The primary endpoint was the objective response rate. Secondary endpoints included duration of response, progression-free survival, overall survival, pharmacokinetics, and incidence of adverse events. Results: Between March 22, 2019, and January 8, 2020, 63 patients were enrolled and treated, 30 in cohort 1, 4 in cohort 2, and 29 in cohort 3. An unplanned preliminary statistical review showed that the efficacy of Debio 1347 was lower than predicted, and the trial was terminated. In total, 3 of 58 evaluable patients had partial responses, representing an objective response rate of 5%, with a further 26 (45%) having stable disease (≥6 weeks duration). Grade ≥3 treatment-related adverse events occurred in 22 (35%) of 63 patients, with the most common being hyperphosphatemia (13%) and stomatitis (5%). Two patients (3%) discontinued treatment due to adverse events. Conclusions: Debio 1347 had manageable toxicity; however, the efficacy in patients with tumors harboring FGFR fusions did not support further clinical evaluation in this setting. Our transcriptomic-based analysis characterized in detail the incidence and nature of FGFR fusions across solid tumors. See related commentary by Hage Chehade et al., p. 4549
Year:
2024
Purpose: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. Experimental Design: A first-in-human, phase I study of KIN-3248 was conducted in patients with advanced solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822). The primary objective was determination of MTD/recommended phase II dose (RP2D). Secondary and exploratory objectives included antitumor activity, pharmacokinetics, pharmacodynamics, and molecular response by circulating tumor DNA (ctDNA) clearance. Results: Fifty-four patients received doses ranging from 5 to 50 mg orally daily across six cohorts. Intrahepatic cholangiocarcinoma (48.1%), gastric (9.3%), and urothelial (7.4%) were the most common tumors. Tumors harbored FGFR2 (68.5%) or FGFR3 (31.5%) alterations—23 (42.6%) received prior FGFR inhibitors. One dose-limiting toxicity (hypersensitivity) occurred in cohort 1 (5 mg). Treatment-related, adverse events included hyperphosphatemia, diarrhea, and stomatitis. The MTD/RP2D was not established. Exposure was dose proportional and concordant with hyperphosphatemia. Five partial responses were observed; 4 in FGFR inhibitor naïve and 1 in FGFR pretreated patients. Pretreatment ctDNA profiling confirmed FGFR2/3 alterations in 63.3% of cases and clearance at cycle 2 associated with radiographic response. Conclusion: The trial was terminated early for commercial considerations; therefore, RP2D was not established. Preliminary clinical data suggest that KIN-3248 is a safe, oral FGFR1-4 inhibitor with favorable pharmacokinetic parameters, though further dose escalation was required to nominate the MTD/RP2D. Significance: KIN-3248 was a rationally designed, next generation selective FGFR inhibitor, that was effective in interfering with both FGFR wild-type and mutant signaling. Clinical data indicate that KIN-3248 is safe with a signal of antitumor activity. Translational science support the mechanism of action in that serum phosphate was proportional with exposure, paired biopsies suggested phospho-ERK inhibition (a downstream target of FGFR2/3), and ctDNA clearance may act as a RECIST response surrogate.
Year:
2024
Antitumor activity. A, Best percent change in target lesions by KIN-3248 starting dose level. Bars are color-coded by the gene (FGFR2 or FGFR3) that was altered according to the molecular report provided for study eligibility evaluation (local testing). Bars are labeled with the best overall response for each evaluable participant. X -axis is labeled with the tumor type of each participant, with the labels color-coded (black or red) to show which participants have been previously treated (*) with one or more FGFR inhibitors. Participants with documented on-target acquired resistance mutations, either by local testing or central ctDNA analysis, are indicated with distinct symbols. B, Twenty-six patients were evaluable for efficacy and were tested by central ctDNA analysis. Box and whisker plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best overall response. C, Scatter plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best % change in target lesions. X-axis direction is reversed. Linear fit with SE. Pearson R = 0.45, P = 0.021.
Year:
2024
Serum phosphate by KIN-3248 C1D1 exposure. Baseline and on-treatment serum phosphate were measured locally in all 54 participants. A, Scatter plot of serum phosphate (mg/dL) after approximately 1 week on KIN-3248 by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between KIN-3248 exposure and serum phosphate level after approximately 1 week of treatment (nominal C1D8: actual study days 6, 7, 8 or 9). Linear fit with SE. Pearson R = 0.55, P = 1.7e-5. B, Scatter plot of initial change in serum phosphate by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between C1D1 KIN-3248 exposure and the initial change (∼1 week) in serum phosphate (PhosC1D8 – PhosC1D1). Pearson R = 0.62, P = 7.1e-7. One participant was missing the C1D1 phosphate measurement, so the screening measurement was used as the baseline value for that participant.
Year:
2024
Serum phosphate by KIN-3248 C1D1 exposure. Baseline and on-treatment serum phosphate were measured locally in all 54 participants. A, Scatter plot of serum phosphate (mg/dL) after approximately 1 week on KIN-3248 by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between KIN-3248 exposure and serum phosphate level after approximately 1 week of treatment (nominal C1D8: actual study days 6, 7, 8 or 9). Linear fit with SE. Pearson R = 0.55, P = 1.7e-5. B, Scatter plot of initial change in serum phosphate by KIN-3248 C1D1 exposure (AUC0–24). Significant correlation between C1D1 KIN-3248 exposure and the initial change (∼1 week) in serum phosphate (PhosC1D8 – PhosC1D1). Pearson R = 0.62, P = 7.1e-7. One participant was missing the C1D1 phosphate measurement, so the screening measurement was used as the baseline value for that participant.
Year:
2024
Purpose: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. Experimental Design: A first-in-human, phase I study of KIN-3248 was conducted in patients with advanced solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822). The primary objective was determination of MTD/recommended phase II dose (RP2D). Secondary and exploratory objectives included antitumor activity, pharmacokinetics, pharmacodynamics, and molecular response by circulating tumor DNA (ctDNA) clearance. Results: Fifty-four patients received doses ranging from 5 to 50 mg orally daily across six cohorts. Intrahepatic cholangiocarcinoma (48.1%), gastric (9.3%), and urothelial (7.4%) were the most common tumors. Tumors harbored FGFR2 (68.5%) or FGFR3 (31.5%) alterations—23 (42.6%) received prior FGFR inhibitors. One dose-limiting toxicity (hypersensitivity) occurred in cohort 1 (5 mg). Treatment-related, adverse events included hyperphosphatemia, diarrhea, and stomatitis. The MTD/RP2D was not established. Exposure was dose proportional and concordant with hyperphosphatemia. Five partial responses were observed; 4 in FGFR inhibitor naïve and 1 in FGFR pretreated patients. Pretreatment ctDNA profiling confirmed FGFR2/3 alterations in 63.3% of cases and clearance at cycle 2 associated with radiographic response. Conclusion: The trial was terminated early for commercial considerations; therefore, RP2D was not established. Preliminary clinical data suggest that KIN-3248 is a safe, oral FGFR1-4 inhibitor with favorable pharmacokinetic parameters, though further dose escalation was required to nominate the MTD/RP2D. Significance: KIN-3248 was a rationally designed, next generation selective FGFR inhibitor, that was effective in interfering with both FGFR wild-type and mutant signaling. Clinical data indicate that KIN-3248 is safe with a signal of antitumor activity. Translational science support the mechanism of action in that serum phosphate was proportional with exposure, paired biopsies suggested phospho-ERK inhibition (a downstream target of FGFR2/3), and ctDNA clearance may act as a RECIST response surrogate.
Year:
2024
Antitumor activity. A, Best percent change in target lesions by KIN-3248 starting dose level. Bars are color-coded by the gene (FGFR2 or FGFR3) that was altered according to the molecular report provided for study eligibility evaluation (local testing). Bars are labeled with the best overall response for each evaluable participant. X -axis is labeled with the tumor type of each participant, with the labels color-coded (black or red) to show which participants have been previously treated (*) with one or more FGFR inhibitors. Participants with documented on-target acquired resistance mutations, either by local testing or central ctDNA analysis, are indicated with distinct symbols. B, Twenty-six patients were evaluable for efficacy and were tested by central ctDNA analysis. Box and whisker plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best overall response. C, Scatter plot of change in mean variant allele frequency of ctDNA after first cycle of KIN-3248 treatment by best % change in target lesions. X-axis direction is reversed. Linear fit with SE. Pearson R = 0.45, P = 0.021.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (28)
Shunsuke Kondo
Professor
Tokyo Women's Medical University
Robert Manguso
Associate Professor
Harvard Medical School
John Bridgewater
UCL Cancer Institute
Taroh Satoh
Professor
Osaka University Hospital
Tomoya Yokota
Chief
Aichi Cancer Center
Nancy Chan
Assistant Professor
NYU School of Medicine
James Harding
Memorial Sloan Kettering Cancer Center
Mitesh Borad
Professor of Medicine
Mayo Clinic
Lipika Goyal
Director of Gastrointestinal Oncology
Stanford University
Andrés Cervantes
Professor of Medicine
University of Valencia
Rachna Shroff
University of Arizona
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Petros Grivas
University of Washington
Jin Won Kim
Professor
Seoul National University Hospital
Milind Javle
PROFESSOR
The University of Texas MD Anderson Cancer Center
Razelle Kurzrock
-
Elena Garralda
Director
-
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Joon Oh Park
Sungkyunkwan University School of Medicine
Ingo Mellinghoff
Department Chair
Memorial Sloan Kettering Cancer Center
Teresa Macarulla
Head of Gastrointestinal and Endocrine Tumor Unit
Hospital Clínic de Barcelona
Kurt Jaeckle
Professor of Neurology and Oncology
Mayo Clinic Florida
Nataliya Uboha
Associate Professor
University of Wisconsin-Madison Carbone Cancer Center
Shumei Kato
University of California, San Diego
Jeesun Yoon
Clinical professor
Seoul National University Hospital
Anita Turk
Assistant Professor of Clinical Medicine
-
Carolina Noble
Københavns Universitet
Sam Lubner
Associate Professor of Medicine
University of Wisconsin-Madison Carbone Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.